Savara (SVRA) Upgraded by ValuEngine to “Sell”
Savara (NASDAQ:SVRA) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
Other research analysts have also recently issued reports about the stock. Roth Capital reduced their price target on shares of Savara from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st. Canaccord Genuity lifted their price target on shares of Savara from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 30th. BidaskClub cut shares of Savara from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 9th. Ladenburg Thalmann Financial Services initiated coverage on shares of Savara in a research report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price target on the stock. Finally, Zacks Investment Research cut shares of Savara from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Savara presently has an average rating of “Buy” and a consensus target price of $23.58.
Savara (SVRA) traded up $0.91 on Wednesday, hitting $13.41. 192,951 shares of the company traded hands, compared to its average volume of 172,125. The firm has a market capitalization of $361.43, a PE ratio of -3.20 and a beta of -0.26. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15. Savara has a twelve month low of $4.60 and a twelve month high of $17.19.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.